Direct Tumor Suppression by Anti-Basigin Antibody and Enhancement of Macrophage-Mediated Cancer Cell Phagocytosis under SIRPα Blockade. (PubMed, Kobe J Med Sci) - Sep 29, 2026 - "Although blockade of the CD47-SIRPα interaction enhances the efficacy of tumor-targeting antibodies such as rituximab, its antitumor activity remains limited in cancers lacking defined tumor-associated antigens...Moreover, combined treatment with the 8H4 antibody and an anti-SIRPα antibody that blocks the CD47-SIRPα interaction markedly enhanced macrophage-mediated ADCP against diverse cancer cell types in vitro. These results suggest that targeting Basigin, particularly in combination with SIRPα blockade, may provide a basis for the development of macrophage-mediated immunotherapies applicable to cancers in which tumor-associated antigens have not yet been identified."
Journal • Oncology • BSG • CD47 • SIRPA
|
|
Naoya Hatano; Takashi Matozaki; Takenori Kotani; Tomoko Takai; Yiyan Yang; Yoji Murata; Yoshimasa Maniwa
|